ICD10monitor September 25, 2024
The Centers for Medicare & Medicaid Services (CMS) has issued a Final Rule that advances policies for the Medicaid Drug Rebate Program (MDRP).
Identifying and Correcting Misclassified Drug Information
Under the MDRP, drug manufacturers are required to report various product and pricing details, including whether a drug is classified as brand-name or generic. This classification is crucial, because it determines the rebate amounts manufacturers owe to states. Brand-name drugs have higher rebate rates than generic drugs.
The new rule introduces statutory provisions to address incorrect reporting and misclassification of drugs in the Medicaid Drug Program (MDP) system. Manufacturers will be obligated to correct any misclassification and pay any unpaid rebates resulting from the incorrect reporting. If manufacturers fail to correct...
Today's Sponsors
Today's Sponsor